UBS rates A2M as Neutral
In the wake of in-house research into the Chinese infant formula market, the broker is more cautious on market outlook but positive on a2. The company is expected to outperform and gain share given its product is the highest regarded yet under-penetrated, and there is scope for price increases.
The broker lifts its target to NZ$12.80 from NZ$11.80 while retaining Neutral.
Media Updates, page-1195
-
- There are more pages in this discussion • 352 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$5.60 |
Change
-0.050(0.88%) |
Mkt cap ! $3.808B | |||
| Open | High | Low | Value | Volume |
| $5.62 | $5.68 | $5.55 | $2.966M | 528.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 19295 | $5.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.60 | 533 | 3 |
View Market Depth
| Last trade - 12.39pm 04/12/2024 (20 minute delay) ? |
| A2M (ASX) Chart |
